1. What conditions has Tudca been studied for?

• HCV-related chronic liver disease / chronic hepatitis C: studied in a small preliminary biopsy-based study (5 patients) assessing hepatocyte proliferation (PCNA) and in a larger randomized placebo-controlled trial in “chronic hepatitis” (150 patients) with biochemical outcomes (aminotransferases).

• Primary biliary cholangitis / primary biliary cirrhosis (PBC): studied in multiple clinical trials including dose-ranging studies and randomized crossover comparisons versus ursodeoxycholic acid (UDCA), and a larger randomized trial in Chinese patients comparing TUDCA vs UDCA for 24 weeks (199 patients).

• Amyotrophic lateral sclerosis (ALS): studied in a small double-blind placebo-controlled “proof of principle” trial (34 patients) as add-on to riluzole for 54 weeks.

• Postprandial (hyperglycaemia-induced) endothelial dysfunction: studied in a small randomized cross-over study in young healthy subjects (12 participants) using flow-mediated dilation (FMD) after an oral glucose challenge.

• Obesity-associated insulin resistance: studied in a randomized placebo-controlled trial in obese adults (20 participants) for 4 weeks using hyperinsulinemic-euglycemic clamp measures.

2. Does it work in treating those conditions? Summarize the evidence.

• HCV-related chronic liver disease / chronic hepatitis

  • Biochemical improvement: In the 150-patient randomized trial (500 mg or 750 mg daily vs placebo for 6 months), TUDCA produced a “consistent decrease” in aminotransferases compared with placebo (p<0.001) and improvement over time (p<0.05).

  • Histology/cell proliferation signal (very preliminary): In 5 HCV patients treated for 3 months, ALT and Knodell score decreased and hepatocyte proliferation (PCNA labeling index) increased (p<0.05). This is suggestive but extremely limited by sample size and design.

  • Clinical endpoints unknown: The studies do not show evidence for reduced cirrhosis progression, decompensation, liver-related mortality, or viral outcomes.

• PBC

  • Improves cholestatic/liver enzymes: Dose-response study (24 patients; 500/1000/1500 mg daily for 6 months) showed significant decreases in serum liver enzymes after the first month across doses; no clear dose-response for biliary enrichment, and no significant difference among doses for enzyme reduction.

  • Comparable to UDCA in short-term trials:

    • 23-patient crossover (500 mg daily each for two 6-month periods): both UDCA and TUDCA improved enzymes vs baseline; no significant difference between them; well tolerated.

    • 12-patient crossover (750 mg/day for 2 months each): focused on absorption/metabolism; suggested pharmacologic advantages for TUDCA (better absorption, less conversion to hydrophobic metabolites) and higher biliary UDCA enrichment during TUDCA vs UDCA (32.6% vs 29.2%; P<.05). Clinical outcome differences were not the main focus.

    • 199-patient randomized comparison (250 mg three times daily for 24 weeks): primary endpoint (ALP reduction >25%) was similar for TUDCA vs UDCA (75.97% vs 80.88%; P=0.453); other biochemical improvements were also similar.

  • Hard outcomes not addressed: These studies primarily report biochemical responses and tolerability, not transplant-free survival or long-term complications.

• ALS

  • Preliminary efficacy signal: In a 34-patient double-blind placebo-controlled trial (TUDCA 1 g twice daily for 54 weeks), the responder proportion was higher with TUDCA (87%) vs placebo (43%) (P=0.021). ALSFRS-R at study end was higher with TUDCA (P=0.007), and progression slopes were slower (P<0.01).

  • Limitations: Small sample size and “proof of principle” design; needs larger confirmatory trials to establish clinical benefit.

• Postprandial endothelial dysfunction (healthy subjects)

  • Acute prevention of FMD impairment: In 12 healthy subjects, a single 1500 mg dose prevented the glucose-challenge–associated reduction in FMD seen with placebo (placebo: -32% at 60 min and -28% at 120 min; TUDCA: -4% and +0.3%, respectively).

  • Mechanistic uncertainty: Glucose and insulin responses were unchanged; oxidative stress markers measured (3-nitrotyrosine, TBARS) were unaltered in both conditions, so the pathway remains uncertain in humans.

• Insulin resistance in obesity

  • Improved insulin sensitivity: In 20 obese adults randomized to 4 weeks of TUDCA (1,750 mg/day) vs placebo, hepatic and muscle insulin sensitivity increased by ~30% with TUDCA (P<0.05) and did not change with placebo.

  • Improved insulin signaling: TUDCA increased muscle insulin signaling markers (phosphorylated IRS(Tyr) and Akt(Ser473)) (P<0.05).

  • ER stress markers did not change: Despite the hypothesized mechanism, measured ER stress markers in muscle/adipose did not change with TUDCA or placebo, leaving the mechanism unresolved.

3. What health benefits does it have?

• Liver-related (most consistent across studies)

  • Improves liver biochemistry: Decreases aminotransferases in chronic hepatitis compared with placebo (150-patient trial; p<0.001) and improves cholestasis/cytolysis-related enzymes in PBC across multiple studies.

  • Potential favorable bile acid profile: Compared with UDCA, TUDCA was better absorbed and underwent reduced biotransformation to more hydrophobic metabolites; lithocholic acid concentrations were consistently higher during UDCA administration in the crossover study (suggesting a potentially “less toxic” bile acid milieu with TUDCA).

  • Possible hepatocyte proliferation signal: In 5 HCV patients, PCNA labeling index increased after TUDCA (p<0.05), suggesting stimulated hepatocyte proliferation; this is intriguing but very preliminary.

• Metabolic/vascular

  • Improved insulin sensitivity in obesity: ~30% increase in hepatic and muscle insulin sensitivity after 4 weeks (20-subject clamp study), plus improved muscle insulin signaling.

  • Protection against acute postprandial endothelial dysfunction: Prevented glucose-induced impairment in flow-mediated dilation in healthy subjects after a single 1500 mg dose.

• Neurologic (ALS)

  • Slower functional decline signal: In a small 54-week trial, TUDCA was associated with a higher responder rate and slower ALSFRS-R decline vs placebo.

4. Does it have any downsides or side effects?

• Diarrhea: Reported as the only side effect in the 24-patient PBC dose-response study (500/1000/1500 mg daily for 6 months).

• Overall tolerability appears good in these studies:

  • ALS trial (1 g twice daily for 54 weeks): “well tolerated” with no between-group differences in adverse events vs placebo.

  • PBC crossover trial (500 mg daily): no patients complained of side effects.

  • 199-patient PBC trial: comparable adverse event rates between TUDCA and UDCA; additionally, pruritus/scratch increased in the UDCA group (1.43% to 10.00%) while no change was reported in the TUDCA group (P=0.023), suggesting TUDCA may be at least not worse for this symptom in that study.

• Limitations of the safety evidence: Many studies are short-term and/or small; rare adverse events and long-term risks cannot be ruled out from these studies alone.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (no genotype-stratified efficacy, safety, dosing, or metabolism results). Therefore:

• No specific genetic variants can be identified (from these studies) as predicting benefit, non-response, or adverse effects to TUDCA.

• What can be inferred (indirectly, with uncertainty): Some studies emphasize differences in absorption and biotransformation versus UDCA (e.g., reduced conversion to more hydrophobic metabolites), which in principle could vary by genetics affecting bile acid transport/metabolism, but the studies provide no direct evidence linking any variant to outcomes.

Research Summary on Tauroursodeoxycholic Acid (TUDCA)

Introduction

Tauroursodeoxycholic acid (TUDCA) is a bile acid that has been the subject of numerous studies due to its potential therapeutic properties. It has been investigated for its role in various physiological mechanisms and potential treatment for several diseases.

Protective Effects in Cellular Stress and Disease

• TUDCA has been shown to disrupt a harmful cycle between oxidative stress and endoplasmic reticulum (ER) stress in beta cell dysfunction, which is mediated by mitochondrial superoxide. It offers potential therapeutic strategies for preserving beta cell function in type 2 diabetes.
• It has demonstrated neuroprotective effects by improving the survival and function of neural grafts in a rat model of Parkinson's disease, suggesting it could be a potential therapeutic strategy for the condition.
• TUDCA's protective effects include preventing mitochondrial damage and reducing steatosis (fat accumulation) caused by ethanol in liver cells, highlighting its potency in reversing ethanol-induced cellular injuries.
• In obese mice, treatment with TUDCA led to increased adiponectin levels, countering the reduction of adiponectin levels due to obesity and ER stress, showcasing its role in maintaining adiponectin levels during obesity.
• The bile acid has been found to protect kidneys from ischemia/reperfusion-induced acute kidney injury by inhibiting ER stress-related pathways.

Effects on Metabolism and Liver Function

• TUDCA treatment in patients with primary biliary cirrhosis resulted in a more pronounced shift toward a hydrophilic bile acid pool, likely due to reduced intestinal biotransformation of TUDCA.
• It has been shown to be effective in increasing bile acid levels in the brain, improving neurological function, and reducing the size of brain infarcts in rat models of stroke.
• The bile acid can also inhibit the proliferation of non-cancerous intestinal cells by causing prolonged ERK1 kinase phosphorylation, which slows the cell cycle and decreases Irs-1 protein levels, suggesting new targets for cancer chemoprevention.

Therapeutic Potential

TUDCA holds potential as a therapeutic agent in a variety of contexts, including diabetes, neurodegenerative diseases, liver diseases, and cancer. Its ability to modulate apoptosis, reduce ER stress, and protect cells from oxidative damage makes it a promising candidate for further clinical research and development.

Ursodeoxycholic Acid (UDCA) Overview

1. Conditions Studied for UDCA Treatment

UDCA has been studied for the treatment of various liver conditions, including primary biliary cholangitis (PBC), gallstones, primary sclerosing cholangitis (PSC), and nonalcoholic fatty liver disease (NAFLD). It has also been explored for its potential benefits in cystic fibrosis-related liver disorders.

2. Efficacy of UDCA in Treating Conditions

UDCA has been proven effective in improving liver function tests and slowing the progression of primary biliary cholangitis (PBC) and in some cases, dissolving gallstones made of cholesterol. However, its efficacy in primary sclerosing cholangitis (PSC) and nonalcoholic fatty liver disease (NAFLD) remains controversial and subject to ongoing research.

3. Health Benefits of UDCA

Beyond its liver-protective effects, UDCA may help reduce cholesterol levels by decreasing the absorption of cholesterol in the intestine and dissolving cholesterol gallstones. It may also have anti-inflammatory and immunomodulatory effects, though these benefits require further study for conclusive evidence.

4. Downsides of UDCA

While UDCA is generally well-tolerated, it can cause side effects such as diarrhea, nausea, and weight gain. In rare cases, it may exacerbate liver disease, especially at high doses or in certain conditions like advanced PSC. Long-term effects and safety profiles are still under investigation.

5. UDCA's Impact on Genetic Variations

Research indicates that genetic variations may influence an individual's response to UDCA treatment, particularly in conditions like primary biliary cholangitis (PBC). Certain genetic markers may predict treatment response or risk of adverse effects, suggesting personalized medicine approaches could optimize UDCA therapy outcomes.

Research Summary on Ursodeoxycholic Acid (UDCA)

UDCA and Beta Cell Function in Rats

UDCA, as tauroursodeoxycholic acid (TUDCA), was found to protect against beta cell dysfunction induced by high glucose levels in rats. It demonstrated similar protective effects as tempol (TPO) and 4-phenylbutyrate (PBA), reducing ER stress markers and preserving beta cell function.

UDCA in Nonalcoholic Steatohepatitis (NASH)

While UDCA and its chemical chaperones reduced ER stress markers in a methionine- and choline-deficient (MCD) diet-induced NASH model in mice, they did not improve liver steatosis, inflammation, or fibrosis, suggesting ER stress may not be central in MCD diet-induced NASH pathogenesis.

UDCA as a Chemopreventive Agent

UDCA was shown to inhibit cell proliferation in the intestines by causing prolonged ERK1 kinase phosphorylation, indicating its potential as a chemopreventive agent against colon cancer.

UDCA in Energy Metabolism

Bile acids, including UDCA, act as signaling molecules, affecting energy metabolism by increasing energy expenditure in tissues, indicating potential targets for metabolic control improvement.

UDCA in Primary Sclerosing Cholangitis (PSC)

Ursodeoxycholic acid is the most researched treatment for PSC, with preliminary studies suggesting benefits, but further research is needed to confirm efficacy.

UDCA and TUDCA in Ethanol-Induced Liver Cell Damage

Both TUDCA and UDCA can protect liver cells from ethanol-induced damage, with TUDCA being particularly potent in reversing ethanol-induced cellular injuries.

UDCA in Parkinson's Disease

TUDCA improved the survival and function of neural grafts in a rat model of Parkinson's disease, suggesting its potential as a therapeutic strategy.

UDCA in Gallstone Disease

UDCA is used for the medical dissolution of cholesterol gallstones, promoting bile desaturation and elimination in a stable form, with minimal side effects.

References:

1. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress
2. Reducing endoplasmic reticulum stress does not improve steatohepatitis in mice fed a methionine- and choline-deficient diet
3. UDCA slows down intestinal cell proliferation by inducing high and sustained ERK phosphorylation
4. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
5. Ubiquitination-induced conformational change within the deiodinase dimer is a switch regulating enzyme activity
6. An update on primary sclerosing cholangitis
7. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance
8. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation
9. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line
10. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study
11. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease
12. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis
13. Treatment of cholesterol gallstones with litholytic bile acids
14. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties--studies on isolated hepatocytes and lipid membrane vesicles
15. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis
16. Liver cell membrane solubilization may control maximum secretory rate of cholic acid in the rat
17. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial
18. Conjugation is rate limiting in hepatic transport of ursodeoxycholate in the rat
19. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1
20. Membrane structural changes support the involvement of mitochondria in the bile salt-induced apoptosis of rat hepatocytes
21. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation
22. Chronic inhibition of endoplasmic reticulum stress and inflammation prevents ischaemia-induced vascular pathology in type II diabetic mice
23. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?
24. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid
25. Epidemiology and natural history of gallstone disease
26. The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure
27. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?
28. Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells
29. The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress
30. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes
31. Neuroprotection by a bile acid in an acute stroke model in the rat
32. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes
33. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria
34. Cellular mechanisms of cholestasis
35. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts
36. Plasma bile acids are not associated with energy metabolism in humans
37. Plasma bile acids are associated with energy expenditure and thyroid function in humans
38. Pharmacological treatment of gallstones. Practical guidelines
39. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects
40. Apoptosis in transgenic mice expressing the P301L mutated form of human tau
41. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats
42. Gallstone opacification during cholelitholytic treatment
43. A central role for JNK in obesity and insulin resistance
44. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids
45. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition
46. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts
47. Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization
48. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease
49. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women
50. Medicinal treatments of cholesterol gallstones: old, current and new perspectives
51. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
52. Acquired gallstone opacification during cholelitholytic treatment with chenodeoxyholic, ursodeoxycholic, and tauroursodeoxycholic acids
53. In vivo protection of the pig liver against ischemia/reperfusion injury by tauroursodeoxycholate
54. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion
55. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects
56. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver: a pilot study in transplant recipients
57. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis
58. Maintenance of hepatic bile acid secretion rate during overnight fasting by bedtime bile acid administration
59. Ursodeoxycholic acid treatment of cholesterol gallstone disease
60. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
61. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate
62. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid
63. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans
64. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period
65. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth
66. Intracellular signaling by the unfolded protein response
67. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells
68. Reduction of endoplasmic reticulum stress using chemical chaperones or Grp78 overexpression does not protect muscle cells from palmitate-induced insulin resistance
69. Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet
70. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease
71. Bile acids: regulation of apoptosis by ursodeoxycholic acid
72. Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells
73. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate
74. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases
75. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line
76. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial
77. Comparative Analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective Effects on Retinal Degeneration Models
78. Bile acids: regulation of apoptosis by ursodeoxycholic acid
79. Tauroursodeoxycholic acid reduces damaging effects of taurodeoxycholic acid on fundus gastric mucosa
80. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis
81. Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy
82. Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling
83. Coenzyme Q 10 supplementation: A potential therapeutic option for the treatment of intrahepatic cholestasis of pregnancy
84. From dried bear bile to molecular investigation: A systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders
85. The Taurine-Conjugated Bile Acid (TUDCA) Normalizes Insulin Secretion in Pancreatic β-Cells Exposed to Fatty Acids: The Role of Mitochondrial Metabolism
86. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid
87. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver
88. The bile acid TUDCA and neurodegenerative disorders: An overview
89. Ursodeoxycholic Acid May Inhibit Environmental Aging-Associated Hyperpigmentation
91. Bile Acids Reduce Prion Conversion, Reduce Neuronal Loss, and Prolong Male Survival in Models of Prion Disease
92. Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement
93. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways
94. Ursodeoxycholic acid treatment of vanishing bile duct syndromes
95. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study
    A Crosignani, G Budillon, L Cimino, C Del Vecchio Blanco, C Loguercio (1998)
96. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study
    A Crosignani, P M Battezzati, K D Setchell, P Invernizzi, G Covini (1996)
97. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study
    A Larghi, A Crosignani, P M Battezzati, G De Valle, M Allocca (1997)
98. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
    A E Elia, S Lalli, M R Monsurrò, A Sagnelli, A C Taiello (2016)
99. Administration of tauroursodeoxycholic acid prevents endothelial dysfunction caused by an oral glucose load
    Lauren K Walsh, Robert M Restaino, Martha Neuringer, Camila Manrique, Jaume Padilla (2016)

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!